Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5 Astrakhan RNA Vaccine
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**H5 Astrakhan RNA Vaccine** is an investigational mRNA-based prophylactic vaccine developed for the prevention of influenza A virus infection, specifically targeting the hemagglutinin (HA) protein from the clade 2.3.4.4b A/Astrakhan/3212/2020 H5N1 virus. The vaccine employs a lipid nanoparticle (LNP) delivery system to introduce nucleoside-modified mRNA encoding the H5 hemagglutinin antigen. The mRNA is translated in host cells, resulting in antigen presentation and subsequent activation of both humoral (antibody-mediated) and cellular (T cell) immune responses. The main mechanism is induction of neutralizing antibodies and HA-specific CD8+ T cell responses, providing immunological protection against infection by H5 influenza viruses. The vaccine has demonstrated immunogenicity and protection in preclinical mouse and ferret models and is currently in Phase 1 clinical trials assessing safety and immunogenicity in healthy adults[1][2][3][5].
- Brand names
- H5 Astrakhan RNA VaccineH-5 Astrakhan RNA VaccineH 5 Astrakhan RNA Vaccine
- Other names
- H5 Astrakhan mRNA VaccineH-5 Astrakhan mRNA VaccineH 5 Astrakhan mRNA Vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on H5 Astrakhan RNA Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5 Astrakhan RNA Vaccine.